The Era of Transdermal Estrogen in Prostate Cancer: A Precision Alternative to LHRH Agonists
In this article
A biological restoration solution to "estrogen deprivation" during androgen deprivation therapy: results of the PATCH and STAMPEDE-1 study.
Biological Rationale: LHRH Agonists vs. Transdermal Estradiol
Withdrawing androgens means cutting off the prostate cancer cell's fuel. However, maintaining the body's estrogen balance during this process is part of our vision of "precision guidance." Unlike older oral estrogens on the market, transdermal estradiol (tE2) bypasses the liver's first-pass effect and minimizes the risk of clotting (thromboembolism).
tE2 patches successfully reduce testosterone to castration levels (< 1.7 nmol/L) by producing negative feedback through the hypothalamic-pituitary axis.
Unlike LHRH agonists, it preserves estrogen levels, supports bone health, and markedly reduces vasomotor symptoms (hot flashes).
Study Design: A Comprehensive Analysis of 15 Years of Data
This phase III non-inferiority study, conducted at 75 centers across the United Kingdom, included 1360 patients between 2007-2022. Of the participants, 85% had T3 disease, and all had a diagnosis of locally advanced (nonmetastatic) prostate cancer.
| Study Arm | Treatment Protocol | Number of Patients (n) |
|---|---|---|
| Experimental Arm (tE2) | Daily 100 μg Estradiol Patches (Every 24 Hours) | 680 |
| Control Arm (LHRH) | Standard LHRH Agonist Injections | 680 |
Clinical Findings: On Target for Efficacy
The study's primary endpoint, metastasis-free survival (MFS) at 3 years, established that estrogen patches were clinically "non-inferior" to standard treatment.
3-Year Metastasis-Free Survival (MFS) Rates
Five-year overall survival rates were also similar: in the tE2 group, the rate was %81.1 , compared with 79.2% in the LHRH group (HR: 0.90). In both groups, castration-level testosterone suppression was consistently maintained for 1 year in 85% of patients.
Safety Profile: A Radical Difference in Quality of Life
The study's most striking results emerge when we compare the biological costs of the treatments in terms of quality of life. Here is the sharp contrast in side effects between the two approaches:
Side Effect Comparison (Grade ≥2 Events)
Clinical Decision Management
While hot flashes and metabolic devastation decrease dramatically in patients using estrogen patches, gynecomastia (breast enlargement) stands out as the most important side effect. However, gynecomastia is a physical change that can be managed with radiotherapy or surgery, whereas the bone loss and hot flashes caused by LHRH agonists can cripple a patient's daily life.
DROZDOGAN Academy Commentary
For years, we followed a philosophy of "zeroing out" in prostate cancer treatment: while reducing testosterone to zero, we also disrupted the patient's overall biological balance through estrogen deprivation. The PATCH and STAMPEDE-1 study whispers this message to us: precision guidance in oncology means not only silencing the cancer cell, but also allowing the rest of the body to live "humanely."
Transdermal estradiol patches are an attempt to rebalance the body's disrupted hormonal orchestra through "restoration." Paying a manageable price such as gynecomastia to gain protection from bone loss, sleepless nights, and adverse effects on cardiovascular health is a revolutionary benefit for our patients. The oncology of the future will be built on treatments that remain true to nature's rhythm in the light of data.
Scientific References and Further Reading
- 1. Langley RE, et al. Transdermal Estradiol Patches in Locally Advanced Prostate Cancer (PATCH/STAMPEDE). N Engl J Med. 2026. doi:10.1056/NEJMoa2511781
- 2. Gilbert DC, et al. The history and evolution of estrogen therapy in prostate cancer. Lancet Oncology. 2021.
- 3. Rosen S, et al. Metabolic and bone health during androgen deprivation therapy. Journal of Urology. 2024.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.